spacer
home > ebr > autumn 2017 > harnessing hybrids
PUBLICATIONS
European Biopharmaceutical Review

Harnessing Hybrids

The increase in biological molecules used for pharmaceutical purposes over the past decade has been profound, now accounting for at least 20% of industry revenues. Therapeutic proteins and peptides are now a part of the portfolio of all but the most specialised pharma companies. These molecules require assays of varying sensitivities to support development and, generally, these have been based on a ligand binding assay (LBA) format, such as enzyme-linked immunosorbent assay (ELISA) or GyrolabTM. Hybrid LBA liquid chromatography-mass spectrometry (LC-MS) methodologies have recently been developed as an alternative approach to these, but what are they? What do they offer the project team and in which circumstances should they be used or not?

Measuring Peptides

Despite Lilly’s US marketing of the first commercially available insulin treatment in 1923, followed by Nordisk’s 1924 release in Scandinavia, no assay was available to measure circulating insulins until the development of the immunoassay by Yallow and Berson in the late 1950s (1). Insulins were instead tested for potency by measuring their ability to reduce blood sugar levels in rabbits. The development of both radioimmunoassays and ELISA-based assays has enabled the rapid and highly sensitive quantitation of biotherapeutics in support of clinical monitoring and drug development programmes over several decades. Many commercial assays for human insulin are available but, despite their advantages, these assays also possess drawbacks, most notably in regard to their specificity.

For example, LBAs developed for human insulin may also bind proinsulin, C peptide and human insulin-derived analogue compounds and their metabolites, a phenomenon known as cross-reactivity (2). Therefore, they tend to give a measure of total insulin activity rather than an individual measure of concentration. While this overall information can be very valuable, for drug development studies, it is more desirable to be able to attribute total activity to particular compounds or their metabolites. This example is one that pertains, to a greater or lesser extent, to all biological molecules, unless a highly specific antibody is available.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Michael Blackburn is Method Development Lead at ARCINOVA. After an MPhil in stable isotopes as tracers of biological processes, Michael worked for the UK Government, developing methods to measure trace concentrations of pollutants. After six years, he moved into the pharmaceutical industry as a Mass Spectrometrist with Sanofi for 13 years and then into contract research with Covance as a Principle Investigator and Method Developer. In 2016, the Alnwick site became ARCINOVA.
spacer
Michael Blackburn
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Strategic Alliance to support efficient, ethical practices in biopharma industry

Hayward, CA and Stockholm, Sweden (07-12-2017) – Two leading drug development and regulatory consultancies announced today that they have formed a new strategic collaboration to help life science companies navigate an increasingly complex global environment. Ethiprax Associates LLC, a leading Compliance and Ethics solutions consultancy based in the US, and NDA Group, a world-leading integrated regulatory/drug development consultancy, are now collaborating to provide the life science industry with truly integrated, trans-Atlantic Compliance-and Risk Management strategies.
More info >>

White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

AIGENPULSE

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

 
Industry Events

9th Global Drug Delivery & Formulation Summit

12-14 March 2018, Maritim proArte Hotel Berlin

The DDF Summit brings the most interesting studies and exciting technologies to you. This year there will be 4 dedicated streams focusing on Small Molecules, Biologics, Technology & Innovation and for the first-time Device Development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement